Clinical Trial Update: Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) [Phase 2]

View source ↗

Summary

This update notes that a Phase 2 trial evaluating a second course of therapy for resistant patent ductus arteriosus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Patent Ductus Arteriosus

Snippet

Sponsor: Shaare Zedek Medical Center | Conditions: Patent Ductus Arteriosus | Phase 2 | Status: WITHDRAWN